Myriad Genetics (Myriad Genetics) Dividend Payout Ratio

: 0.00 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

Myriad Genetics's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Myriad Genetics's Dividend Payout Ratio or its related term are showing as below:

MYGN's Dividend Payout Ratio is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 0.41
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-23), the Dividend Yield % of Myriad Genetics is 0.00%.

Myriad Genetics's Dividends per Share for the months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Myriad Genetics Dividend Payout Ratio Historical Data

The historical data trend for Myriad Genetics's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Myriad Genetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividend Payout Ratio																-	-	-	-	-

Competitive Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myriad Genetics Dividend Payout Ratio Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Dividend Payout Ratio falls into.

Myriad Genetics Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Myriad Genetics's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-2.104
	=	N/A

Myriad Genetics's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	0.04
	=	0.00

Myriad Genetics (NAS:MYGN) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Myriad Genetics Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics (Myriad Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » Dividend Payout Ratio

Comparable Companies

TWST NEO VCYT GH OPK LAB FLGT CSTL CDNA SHC TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN

Traded in Other Exchanges

MYD:Germany

Address

320 Wakara Way, Salt Lake City, UT, USA, 84108

Website

https://www.myriad.com

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Executives

Richard Bryan Riggsbee	officer: Chief Financial Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Nicole Lambert	officer: Chief Operating Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Margaret Ancona	officer: SVP, Chief of Staff	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong	officer: Chief Legal Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman	officer: Chief People Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro	director
Dale Muzzey	officer: Chief Scientific Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Kevin Richard Haas	officer: Chief Technology Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk	officer: Chief Accounting Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Lee Nisley Newcomer	director	264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Rashmi Kumar	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jayne B. Hart	officer: Executive VP Human Resources	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jerry S Lanchbury	officer: Senior V.P. - Research	320 WAKARA WAY, SALT LAKE CITY UT 84108